Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: F30 CA 243307, R01 CA175061, R01 CA208514
National Institute of General Medical Sciences
Grant: T32 GM008716
NCI NIH HHS
Grant: F30 CA243307
NCI NIH HHS
Grant: R01 CA175061
NCI NIH HHS
Grant: R01 CA208514
National Institutes of Health
Grant: 5T32GM008716-17
Training Program for Medical Scientists
National Institutes of Health
Grant: 7R01CA208514-05
Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells
National Institutes of Health
Grant: 1R01CA175061-01A1
Costimulatory mechanisms of antitumor Th17 cell immunity
National Institutes of Health
Grant: 1F30CA243307-01
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
FWCI
0.39
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals